NCT03646292 - Antidiabetic Drugs for Steatotic Liver Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2018

Primary Completion Date

June 16, 2022

Study Completion Date

June 16, 2022

Conditions

MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 DiabetesDigestive System DiseaseLiver DiseasesFatty LiverMetabolic Dysfunction-Associated Steatotic Liver DiseaseNon-Alcoholic Fatty Liver DiseaseHypoglycemic AgentsPhysiological Effects of DrugsSodium-Glucose Cotransporter 2 InhibitorsPioglitazoneMolecular Mechanisms of Pharmacological ActionEmpagliflozinThiazolidinediones

Interventions

DRUG

Pioglitazone

The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.

DRUG

Empagliflozin

The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.

DRUG

Combination of pioglitazone and empagliflozin

The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.

Trial Locations (1)

03722

Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER